Avexa Limited has today announced that it has entered into a license agreement with the Shanghai Institute of Organic Chemistry (SIOC) to develop one of Avexa’s HIV integrase inhibitor series. Under the terms and conditions of the license SIOC will be responsible for all future development costs for the program in China and will pay Avexa 50% of any net commercialisation revenues. Avexa retains all development and marketing rights for the program outside of the China region.

“This series of molecules has shown a high level of potency similar to the existing HIV integrase inhibitors on the market or in development. The synthesis of this series of molecules is relatively simple and provides opportunities in the Chinese market,” said interim CEO Dr Jonathan Coates.


• All future development costs for China covered by the partner
• Avexa to receive 50% of all net revenues in China
• Avexa to retain all development and marketing rights for the rest of the world

Source: Avexa